Elan Corporation PLC - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Elan Corporation PLC Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Elan Corporation PLC. The Group's principal activity is discovering, developing, manufacturing and marketing advanced therapies in neurodegenerative diseases, autoimmune diseases and severe pain. The Group's operations are carried out through two divisions. Elan Drug Technologies focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry. Biopharmaceuticals relates to the research, development and commercial activities in the areas of autoimmune diseases, neurodegenerative diseases and specialty business. The Group's product brands are Azactam, Maxipime, MXDAS, NanoCrystal, Naprelan, Prialt, SODAS, Tysabri and Verelan.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report